Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dabigatran (BIBR 953ZW) 是一种口服抗凝剂,是一种可逆的,竞争性的直接凝血酶 (thrombin) 抑制剂,Ki=4.5 nM。它也抑制凝血酶诱导的血小板聚集 (IC50=10 nM)。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 397 | 现货 | ||
2 mg | ¥ 611 | 现货 | ||
5 mg | ¥ 816 | 现货 | ||
10 mg | ¥ 1,490 | 现货 | ||
25 mg | ¥ 2,480 | 现货 | ||
50 mg | ¥ 3,670 | 现货 | ||
100 mg | ¥ 5,250 | 现货 | ||
500 mg | ¥ 10,600 | 现货 |
产品描述 | Dabigatran (BIBR 953ZW) is a THROMBIN inhibitor which acts by binding and blocking thrombogenic activity and the prevention of thrombus formation. It is used to reduce the risk of stroke and systemic EMBOLISM in patients with nonvalvular atrial fibrillation. |
靶点活性 | Thrombin:9.3 nM |
体外活性 | BIBR 953 is a very potent anticoagulant. BIBR 953 shows that the terminal phenyl can be substituted by the more hydrophilic 2-pyridyl group without substantial loss of activity. BIBR 953 inhibits thrombin, plasmin, factor Xa, trypsin, tPA and activated protein C with Ki of 4.5 nM, 1.7 μM, 3.8 μM, 50 nM, 45 μM and 20 μM, respectively. [1] BIBR 953 specifically and reversibly inhibits thrombin. [2] |
体内活性 | BIBR 953 exhibits the most favorable activity profile following i.v. administration to rats. [1] The bioavailability of dabigatran after p.o. administration of dabigatran etexilate is 7.2%. Dabigatran is predominantly excreted in the feces after p.o. treatment and in the urine after i.v. treatment. The mean terminal half-life of dabigatran is approximately 8 hours. Dabigatran acylglucuronides accounts for 0.4% and 4% of the dose in urine after p.o. and i.v. dosing, respectively. [3] |
别名 | BIBR 953, BIBR 953ZW, 达比加群 |
分子量 | 471.51 |
分子式 | C25H25N7O3 |
CAS No. | 211914-51-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
0.1 M HCL: 12.5 mg/mL (26.51 mM), Sonication is recommended.
DMSO: < 1 mg/mL (insoluble or slightly soluble)
H2O: < 0.1 mg/mL (insoluble)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
0.1 M HCL | 1 mM | 2.1208 mL | 10.6042 mL | 21.2085 mL | 53.0211 mL |
5 mM | 0.4242 mL | 2.1208 mL | 4.2417 mL | 10.6042 mL | |
10 mM | 0.2121 mL | 1.0604 mL | 2.1208 mL | 5.3021 mL | |
20 mM | 0.106 mL | 0.5302 mL | 1.0604 mL | 2.6511 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Dabigatran 211914-51-1 Proteases/Proteasome Thrombin Inhibitor BIBR 953 inhibit BIBR 953ZW BIBR953 达比加群 BIBR-953 inhibitor